All News

Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis
June 06, 2025

RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.

INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis
June 06, 2025

RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.

Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
June 06, 2025

RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.

Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment
June 06, 2025

RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.

Patient Survey Highlights Importance of Itch Relief, Personalized Guidance in Atopic Dermatitis Treatment
June 06, 2025

RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.

Women’s Health Takeaways for Primary Care: Expert Insights from ACOG 2025
June 06, 2025

Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.

Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds
June 05, 2025

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Social Determinants of Health Affect Use of HRT During Menopause, Study Suggests
June 04, 2025

Social determinants including partner status, smoking history, and BMI were significantly associated with reduced access to effective hormone therapy for menopausal women.

Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
June 04, 2025

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose
June 04, 2025

Your daily dose of the clinical news you may have missed.